Personalized RNA Therapy Engine RNAForge Launches: Custom mRNA Drug Design from Gene Mutation Analysis in Just 96 Hours

BioNTech and Google DeepMind jointly launched the RNAForge personalized RNA therapy design platform on September 6. The platform can automatically identify pathogenic mutations from a patient's whole genome sequencing data, design personalized mRNA therapeutics targeting those mutations, and output RNA sequences and lipid nanoparticle formulations ready for GMP production.

RNAForge's core consists of specially trained RNA design AI models. The first model screens genomic data for pathogenic mutation sites with 97% accuracy. The second designs corrective mRNA sequences based on mutation type, including customized codon optimization, 5' cap structures, and 3' poly-A tails. The third predicts in vivo mRNA stability and translation efficiency, automatically adjusting sequences to optimize efficacy.

BioNTech CEO Ugur Sahin said: "RNAForge compresses personalized RNA therapy design from months to 96 hours. This means for certain rare genetic disease patients, we may for the first time be able to offer treatment truly targeted to their individual mutations."

RNAForge is currently in early access, with first partners including 10 rare disease treatment centers across Europe and the United States.